Abstract
Introduction: Behavioural and psychological symptoms of dementia (BPSD) have a high prevalence in dementia. There are many suggested management strategies for BPSD. Neuroleptics have a role in the management of these symptoms, but the potential benefits must be weighed against the significant risks such as cerebrovascular adverse events and mortality. The 3rd Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD, 2007) recommends careful review and documentation of BPSD, with efforts at modifying behaviours through non pharmacological methods first. Neuroleptic medications may be necessary for symptoms of severe agitation, aggression and psychosis where there is risk of harm to the patient and/or others. The CCCDTD3 recommends that if used, these medications should be reviewed for potential taper or withdrawal after 3 months of stability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
